摘要
目的观察晚期非小细胞肺癌患者应用脐血CIK细胞联合吉西他滨和顺铂的疗效及患者生活质量的变化,评价其临床应用价值。方法将52例确诊的老年晚期非小细胞肺癌患者半随机分成两组。观察组25例给予脐血来源的细胞因子诱导的杀伤细胞静脉输入,联合吉西他滨和顺铂化疗;对照组27例给予吉西他滨和顺铂化疗。结果观察组中部分缓解(PR)6例,稳定(SD)10例,进展(PD)9例,对照组中PR 3例,SD 7例,PD 17例,两组有效率差异有统计学意义(P<0.05)。治疗后两组生活质量评分,观察组优于对照组(P<0.05)。观察组治疗后不良反应发生率低于对照组(P<0.05)。CIK细胞输注的主要不良反应为发热。结论静脉输注脐血CIK细胞联合吉西他滨和顺铂治疗晚期非小细胞肺癌,是一种新的、安全有效的治疗方法,能有效改善患者的生活质量,不良反应少,值得临床推广应用。
life,to analyze the clinical value .Methods Fifty-two patients with advanced non -small cell lung cancer were ran-domly divided into two groups .There were 25 patients in the observation group , 27 patients in the control group .The observation group were treated by GP plus CIK cell immunotherapy program and the control group of 27 patients were treated by GP program .Efficacy and adverse reactions were evaluated .QLQ-LC13 scale was used before and after treatment to assess the quality of life .Results The observation group showed PR in 6 cases, SD in 10 cases, PD in 9 cases, the control group showed PR in 3 cases, SD in 7 cases, PD in 17 cases.The difference between the two groups was statistically significant（ P＆lt;0.05 ） .After treatment , the life quality scores in the observation group was better than that in the control group （ P＆lt;0.05 ） .The adverse reaction in the observation group was lower than the control group（P＆lt;0.05）.In the observed group, the probability of fever was higher than that of the control group （P＆lt;0.05 ） .Conclusion The treatment of cord blood cytokine -induced killer cells combined with gemcitabine and cispl-atin for advanced non-small cell lung cancer patients is safe and effective .It can improve quality of life of the patients with advanced non-small cell lung cancer .The treatment will be worth popularizing in clinical applications . 〈br〉 Objective To observe the efficacy of cord blood cytokine-induced killer cells combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer ,and to study patients′quality of＆amp;nbsp;life,to analyze the clinical value .Methods Fifty-two patients with advanced non -small cell lung cancer were ran-domly divided into two groups .There were 25 patients in the observation group , 27 patients in the control group .The observation group were treated by GP plus CIK cell immunotherapy program and the control group of 27 patients were treated by GP program .Efficacy and adverse reactions were evaluated .QLQ-LC13 scale was used before and after treatment to assess the quality of life .Results The observation group showed PR in 6 cases, SD in 10 cases, PD in 9 cases, the control group showed PR in 3 cases, SD in 7 cases, PD in 17 cases.The difference between the two groups was statistically significant（ P＆lt;0.05 ） .After treatment , the life quality scores in the observation group was better than that in the control group （ P＆lt;0.05 ） .The adverse reaction in the observation group was lower than the control group（P＆lt;0.05）.In the observed group, the probability of fever was higher than that of the control group （P＆lt;0.05 ） .Conclusion The treatment of cord blood cytokine -induced killer cells combined with gemcitabine and cispl-atin for advanced non-small cell lung cancer patients is safe and effective .It can improve quality of life of the patients with advanced non-small cell lung cancer .The treatment will be worth popularizing in clinical applications .
出处
《中国临床新医学》
2014年第2期121-124,共4页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词
吉西他滨
化疗
脐血CIK细胞
非小细胞肺癌
Gemcitabine
Chemotherapy
Cord blood cytokine-induced killer cells
Non-small cell lung cancer
